From Wikipedia, the free encyclopedia
Chemical compound
Uridine triacetate
Trade names Vistogard, Xuriden Other names vistonuridine
AHFS /
Drugs.com
Monograph
MedlinePlus
a616020
License data
Routes of administration
By mouth
ATC code
Legal status
Metabolism Pyrimidine catabolic pathway
Onset of action
Tmax = 2–3 hours
Elimination half-life 2–2.5 hours
Excretion
Kidney
[(2R,3R,4R,5R)-3,4-diacetyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl acetate
CAS Number
PubChem
CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (
EPA )
ECHA InfoCard
100.021.710
Formula C 15 H 18 N 2 O 9
Molar mass 370.314 g·mol−1 3D model (
JSmol )
CC(=O)OCC1C(C(C(O1)N2C=CC(=O)NC2=O)OC(=O)C)OC(=O)C
InChI=1S/C15H18N2O9/c1-7(18)23-6-10-12(24-8(2)19)13(25-9(3)20)14(26-10)17-5-4-11(21)16-15(17)22/h4-5,10,12-14H,6H2,1-3H3,(H,16,21,22)/t10-,12-,13-,14-/m1/s1
Key:AUFUWRKPQLGTGF-FMKGYKFTSA-N
Uridine triacetate (
INN ),
[1] formerly known as vistonuridine , is an orally active tri-
acetylated
prodrug of
uridine
[2] used:
in the treatment of hereditary
orotic aciduria (brand name Xuriden
ZOOR -ə-den );
[3]
to treat people following an overdose of
chemotherapy drugs
5-fluorouracil (5-FU) or
capecitabine regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration (brand name Vistogard ).
[4]
[5]
[6]
[7]
[8]
Uridine triacetate was developed, manufactured and distributed by
Wellstat Therapeutics . It was granted
breakthrough therapy designation by the U.S.
Food and Drug Administration (FDA) and approved for use in the United States in 2015.
[9]
[10]
[11]
References
^
"International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65" (PDF) . World Health Organization. p. 92. Retrieved 12 March 2017 .
^
"Uridine triacetate — DrugBank Page" . 12 March 2017.
^
"Xuriden- uridine triacetate granule" . DailyMed . 16 December 2019. Retrieved 20 October 2020 .
^
"Vistogard- uridine triacetate granule" . DailyMed . 15 November 2018. Retrieved 20 October 2020 .
^
"BTG Announces FDA Approval of Vistogard (Uridine Triacetate) as Antidote to Overdose and Early Onset, Severe, or Life-Threatening Toxicities from Chemotherapy Drugs 5-Fluorouracil (5-FU) or Capecitabine" . BTG International Ltd. 11 December 2015. Retrieved 12 March 2017 .
^
"Approved Drugs — Uridine Triacetate" . U.S. Food and Drug Administration. Archived from
the original on 3 March 2016. Retrieved 12 March 2017 .
^ Cada DJ, Mbogu U, Bindler RJ, Baker DE (June 2016).
"Uridine Triacetate" . Hospital Pharmacy . 51 (6): 484–8.
doi :
10.1310/hpj5106-484 .
PMC
4911989 .
PMID
27354750 .
^ Ison G, Beaver JA, McGuinn WD, Palmby TR, Dinin J, Charlab R, et al. (September 2016).
"FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs" . Clinical Cancer Research . 22 (18): 4545–4549.
doi :
10.1158/1078-0432.CCR-16-0638 .
PMID
27401247 .
S2CID
25746700 .
^
"Xuriden (uridine triacetate) oral granules" . U.S.
Food and Drug Administration (FDA) . 8 October 2015.
Archived from the original on 8 December 2019. Retrieved 7 December 2019 . This article incorporates text from this source, which is in the
public domain .
^
"Drug Trials Snapshots: Xuriden" . U.S.
Food and Drug Administration (FDA) . 4 September 2015.
Archived from the original on 8 December 2019. Retrieved 8 December 2019 . This article incorporates text from this source, which is in the
public domain .
^
"Previous Cumulative CY CDER BT Approvals" (PDF) . U.S.
Food and Drug Administration (FDA) .
Archived from the original on 8 December 2019. Retrieved 7 December 2019 . This article incorporates text from this source, which is in the
public domain .
External links